A lot of people are going to get rich(er) at this tiny Wall Street firm

Blair EffronScreenshot/CNBCBlair Effron, co-founder of Centerview Partners

It has been an incredible year for Centerview Partners, the New York-based boutique advisory firm led by Blair Effron.

The firm has landed roles on some of the biggest deals of the year, working on the Pfizer-Allergan $160 billion megadeal.

It also has a role on the $20 billion Jarden-Newell Rubbermaid deal announced this week.

The firm has worked on deals worth $464 billion so far this year, and has hauled in more than $500 million in revenue from M&A deals, according to estimates from Dealogic.

To put that into context, Centerview lists 31 partners on its website. That works out at $16.4 million in revenue per partner.

According to various estimates, the boutique has between 200 and 225 employees. Even using the high range of that estimate, it means that on $508 million, Centerview made an average of more than $2.25 million per worker on its mega-M&A year.

Business Insider’s Ben Moshinsky revealed details on Centerview’s UK business earlier this week. The firm paid its top UK partner an £8 million ($12 million) profit share in 2015, according to its accounts.

Those accounts showed an operating profit of £18.6 on revenues of £26.3 million, giving it an operating margin of 71%. Almost all of that operating profit was paid out to members in compensation.

Centerview ranks #12 for M&A globally

Centerview 2DealogicThe bank also placed twelfth worldwide for deals revenue

NOW WATCH: JIM CRAMER: This is where you should invest your first $10,000

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.